JP2001521497A - 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ - Google Patents
精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせInfo
- Publication number
- JP2001521497A JP2001521497A JP54116898A JP54116898A JP2001521497A JP 2001521497 A JP2001521497 A JP 2001521497A JP 54116898 A JP54116898 A JP 54116898A JP 54116898 A JP54116898 A JP 54116898A JP 2001521497 A JP2001521497 A JP 2001521497A
- Authority
- JP
- Japan
- Prior art keywords
- combination
- mirtazapine
- antipsychotic
- antipsychotics
- lidol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. ミルタザピンと抗精神病剤からなる組み合わせ。 2. 該抗精神病剤が典型または異型抗精神病剤であることを特徴とする、請求 項1に記載の組み合わせ。 3. 該抗精神病剤が、アセプロマジン、クロルプロエタジン、クロルプロマジ ン、シアメマジンフルオプロマジン、メトトリメプラジン、プロマジン、メソリ ダジン、ペリシアジン、ピペラセタジン、ピポチアジン、スルホリダジン、チオ リダジン、アセトフェナジン、カルフェナジン、ジキシラジン、フルフェナジン 、ペラジン、ペルフェナジン、プロクロルペラジンチオプロパザート、チオプロ ペラジン、トリフルペラジン、クロルプロチキセン、フルペンチクソール、チオ チキセン、ズクロペンチクソール、ベンペリドール、ブロムペリドール、ドロペ リドール、フルアニソン、ハロペリドール、メルペロン、モペロン、ピパムペロ ン、スピペロン、チミペロン、トリフルペリドール、フルスピリレン、ペンフル リドール、ピモジド、アミスルプリド、ラクロプリド、レモキシプリド、スルピ リド、スルトプリド、チアプリド、モリンドン、オキシペルチン、クロザ ピン、ロキサピン、リスペリドン、オランザピン、セルチンドール、クエチアピ ン、及びジプラシドンから選択されることを特徴とする、請求項1に記載の組み 合わせ。 4. 該抗精神病剤が、アセプロマジン、クロルプロメタジン、クロルプロマジ ン、シアメマジンフルオプロマジン、メトトリメプラジン、プロマジン、メソリ ダジン、ペリシアジン、ピペラセタジン、ピポチアジン、スルホリダジン、チオ リダジン、アセトフェナジン、カルフェナジン、ジキシラジン、フルフェナジン 、ペラジン、ペルフェナジン、プロクロルペラジンチオプロパザート、チオプロ ペラジン、トリフルペラジン、クロルプロチキセン、フルペンチクソール、チオ チキセン、ズクロペンチクソール、ベンペリドール、ブロムペリドール、ドロペ リドール、フルアニソン、ハロペリドール、メルペロン、モペロン、ピパムペロ ン、スピペロン、チミペロン、トリフルペリドール、フルスピリレン、ペンフル リドール、ピモジド、アミスルプリド、ラクロプリド、レモキシプリド、スルピ リド、スルトプリド、チアプリド、モリンドン、オキシペルチン、クロザピン、 ロキサピン、リスペリドン、及びオランザピンから選択されることを特徴とする 、請求項1に記載の組み合わせ。 5. 医療に用いられることを特徴とする、請求項1から請求項4までのいずれ か一項に記載の組み合わせ。 6. 1つもしくはそれ以上の医薬的に許容可能な担体と組み合わせた請求項1 から請求項4までのいずれか一項に記載の組み合わせからなる製剤。 7. 動物における精神異常症の処置法であって、治療上有効量の請求項1から 請求項4までのいずれかで定められた組み合わせ、または請求項6に記載の製剤 で該動物を処置することからなる処置法。 8. 精神異常症を治療及び/又は予防するために抗精神病剤と同時または逐次 的に投与するための薬剤の製造におけるミルタザピンの使用。 9. 精神異常症を治療及び/又は予防するためにミルタザピンと同時または逐 次的に投与するための薬剤の製造における抗精神病剤の使用。 10. 精神異常症を治療及び/又は予防するための薬剤の製造におけるミルタ ザピンと抗精神病剤の使用。 11. ミルタザピン及び抗精神病剤から選択される少なくとも1つの活性成分 を含み、更に、ミルタザピンと抗精神病剤か らなる組み合わせにおけるその活性成分、またはそれらの活性成分の使用法に関 する指示を含む情報添付文書を含んでいる患者用包装。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97200881 | 1997-03-27 | ||
EP97202785 | 1997-09-11 | ||
EP97202785.8 | 1997-09-11 | ||
EP97200881.7 | 1997-09-11 | ||
PCT/EP1998/001920 WO1998043646A1 (en) | 1997-03-27 | 1998-03-25 | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009168383A Division JP5023315B2 (ja) | 1997-03-27 | 2009-07-17 | 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001521497A true JP2001521497A (ja) | 2001-11-06 |
JP2001521497A5 JP2001521497A5 (ja) | 2005-11-10 |
JP4377456B2 JP4377456B2 (ja) | 2009-12-02 |
Family
ID=26146283
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54116898A Expired - Fee Related JP4377456B2 (ja) | 1997-03-27 | 1998-03-25 | 精神異常症を治療及び/又は予防するための組成物 |
JP2009168383A Expired - Fee Related JP5023315B2 (ja) | 1997-03-27 | 2009-07-17 | 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009168383A Expired - Fee Related JP5023315B2 (ja) | 1997-03-27 | 2009-07-17 | 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP0969845B1 (ja) |
JP (2) | JP4377456B2 (ja) |
KR (1) | KR100577865B1 (ja) |
CN (1) | CN1226036C (ja) |
AR (1) | AR012193A1 (ja) |
AT (1) | ATE318604T1 (ja) |
AU (1) | AU726194B2 (ja) |
BR (1) | BR9808077A (ja) |
CA (1) | CA2284551C (ja) |
CZ (1) | CZ298105B6 (ja) |
DE (1) | DE69833645T2 (ja) |
DK (1) | DK0969845T3 (ja) |
ES (1) | ES2259207T3 (ja) |
HK (1) | HK1023293A1 (ja) |
HU (1) | HUP0002742A3 (ja) |
ID (1) | ID22283A (ja) |
IL (1) | IL123716A (ja) |
NO (1) | NO994673L (ja) |
NZ (1) | NZ337618A (ja) |
PL (1) | PL191449B1 (ja) |
PT (1) | PT969845E (ja) |
RU (1) | RU2222330C2 (ja) |
TR (1) | TR199902334T2 (ja) |
TW (1) | TW587938B (ja) |
WO (1) | WO1998043646A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009137970A (ja) * | 1996-06-19 | 2009-06-25 | Nv Organon | ミルタザピンと1種類以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物 |
JP2014510023A (ja) * | 2011-04-05 | 2014-04-24 | 大塚製薬株式会社 | ブレクスピプラゾール又はその塩及び第二薬剤を含有する中枢神経疾患を治療するための組合せ薬剤 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6280763B1 (en) | 1999-05-10 | 2001-08-28 | Pierce Management, Llc | Apparatus and method for transdermal delivery of bupropion |
FR2797399B1 (fr) * | 1999-08-13 | 2002-10-18 | Aventis Pharma Sa | Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines |
US6350773B1 (en) | 1999-12-10 | 2002-02-26 | American Home Products Corporation | Therapeutic combinations of (S)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro 7H-1,4-dioxino{2,3-e}indol-8-one and neuroleptics for the treatment or prevention of psychotic disorders |
FR2802101B1 (fr) * | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
HUP0204050A3 (en) * | 2000-01-19 | 2004-09-28 | Akzo Nobel Nv | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone |
US6495154B1 (en) * | 2000-11-21 | 2002-12-17 | Vivus Inc. | On demand administration of clomipramine and salts thereof to treat premature ejaculation |
EP1795199A3 (en) * | 2001-02-06 | 2007-07-25 | AstraZeneca AB | Quetiapine for the treatment of substance dependence or substance abuse |
DE60219761T2 (de) | 2001-02-06 | 2008-01-17 | Astrazeneca Ab | Verwendung von quetiapin für die behandlung von kokain-abhängigkeit |
TW200517106A (en) | 2003-10-29 | 2005-06-01 | Wyeth Corp | Sustained release pharmaceutical compositions |
EP1708790B1 (en) * | 2003-12-02 | 2010-04-21 | PharmaNeuroBoost N.V. | Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders |
EP1547650A1 (en) * | 2003-12-02 | 2005-06-29 | B & B Beheer NV | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US7855195B2 (en) | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US7884096B2 (en) | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
PT1541197E (pt) * | 2003-12-02 | 2009-06-04 | Pharmaneuroboost N V | Utilização de pipamperona e de um sndri, snri ou ssri para o tratamento de patologias do temperamento ou da ansiedade |
RU2006146612A (ru) | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
KR101390012B1 (ko) * | 2006-06-09 | 2014-04-29 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 신규한 테이프 제제 |
DE102012011839B4 (de) | 2012-06-14 | 2018-03-22 | Norbert Müller | Verwendung von Interferon-gamma in einem Verfahren zur Behandlung von psychiatrischen Erkrankungen |
RU2509560C1 (ru) * | 2013-03-22 | 2014-03-20 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Новые терапевтические комбинации миртазапина для применения при болевых расстройствах |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2410821A1 (de) * | 1974-03-07 | 1975-09-18 | Hoechst Ag | Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung |
CA1327008C (en) * | 1988-01-15 | 1994-02-15 | Walter Merz | Anti-psychotic imidazobenzodiazepine |
DE69005992T2 (de) * | 1989-12-06 | 1994-05-05 | Akzo Nv | Psychotropische Wirkstoffe enthaltende stabilisierte Lösungen. |
ZA935078B (en) * | 1992-07-15 | 1994-02-07 | Nicolaas Johannes Jaco Loetter | Pharmaceutical composition |
PT669128E (pt) * | 1992-11-17 | 2000-06-30 | Yoshitomi Pharmaceutical | Micro-esfera de libertacao sustentada contendo antipsicoticos e processo para produzir a mesma |
JPH07242669A (ja) * | 1994-03-07 | 1995-09-19 | Akikazu Ogawa | 四環系とブチロフェノン誘導体を化学結合した化合物 |
-
1998
- 1998-03-17 IL IL12371698A patent/IL123716A/xx not_active IP Right Cessation
- 1998-03-17 TW TW087103929A patent/TW587938B/zh not_active IP Right Cessation
- 1998-03-25 CA CA002284551A patent/CA2284551C/en not_active Expired - Fee Related
- 1998-03-25 NZ NZ337618A patent/NZ337618A/en unknown
- 1998-03-25 CN CNB98803770XA patent/CN1226036C/zh not_active Expired - Fee Related
- 1998-03-25 AT AT98919209T patent/ATE318604T1/de not_active IP Right Cessation
- 1998-03-25 ID IDW991022A patent/ID22283A/id unknown
- 1998-03-25 DK DK98919209T patent/DK0969845T3/da active
- 1998-03-25 WO PCT/EP1998/001920 patent/WO1998043646A1/en active IP Right Grant
- 1998-03-25 ES ES98919209T patent/ES2259207T3/es not_active Expired - Lifetime
- 1998-03-25 PL PL335890A patent/PL191449B1/pl unknown
- 1998-03-25 HU HU0002742A patent/HUP0002742A3/hu unknown
- 1998-03-25 EP EP98919209A patent/EP0969845B1/en not_active Expired - Lifetime
- 1998-03-25 TR TR1999/02334T patent/TR199902334T2/xx unknown
- 1998-03-25 AU AU72139/98A patent/AU726194B2/en not_active Ceased
- 1998-03-25 KR KR1019997008745A patent/KR100577865B1/ko not_active IP Right Cessation
- 1998-03-25 DE DE69833645T patent/DE69833645T2/de not_active Expired - Lifetime
- 1998-03-25 PT PT98919209T patent/PT969845E/pt unknown
- 1998-03-25 BR BR9808077-6A patent/BR9808077A/pt not_active Application Discontinuation
- 1998-03-25 CZ CZ0343199A patent/CZ298105B6/cs not_active IP Right Cessation
- 1998-03-25 RU RU99122597/14A patent/RU2222330C2/ru not_active IP Right Cessation
- 1998-03-25 JP JP54116898A patent/JP4377456B2/ja not_active Expired - Fee Related
- 1998-03-27 AR ARP980101406A patent/AR012193A1/es not_active Application Discontinuation
-
1999
- 1999-09-24 NO NO19994673A patent/NO994673L/no not_active Application Discontinuation
-
2000
- 2000-05-02 HK HK00102643A patent/HK1023293A1/xx not_active IP Right Cessation
-
2009
- 2009-07-17 JP JP2009168383A patent/JP5023315B2/ja not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009137970A (ja) * | 1996-06-19 | 2009-06-25 | Nv Organon | ミルタザピンと1種類以上の選択的セロトニン再取り込み阻害剤とを含む医薬組成物 |
JP2014510023A (ja) * | 2011-04-05 | 2014-04-24 | 大塚製薬株式会社 | ブレクスピプラゾール又はその塩及び第二薬剤を含有する中枢神経疾患を治療するための組合せ薬剤 |
JP2017031155A (ja) * | 2011-04-05 | 2017-02-09 | 大塚製薬株式会社 | ブレクスピプラゾール又はその塩及び第二薬剤を含有する中枢神経疾患を治療するための組合せ薬剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5023315B2 (ja) | 精神異常症の治療または予防処置のための、ミルタザピンと抗精神病剤の新規組み合わせ | |
US6150353A (en) | Therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders | |
JP2019131598A5 (ja) | ||
AU2017200396B2 (en) | Methods for treating antipsychotic-induced weight gain | |
JP6511492B2 (ja) | 女性胃不全麻痺に関係する症状の処置 | |
JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
ZA200509904B (en) | Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight | |
AU2008259864B2 (en) | Methods and compositions for administration of Oxybutynin | |
JPH07509476A (ja) | 高眼内圧の治療または予防のための医薬 | |
JP2003520237A (ja) | 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤 | |
JP2003500446A (ja) | メラトニンの治療的使用法 | |
JPH037218A (ja) | 薬剤組成物 | |
CN101247796A (zh) | 用于治疗精神病的组合物 | |
ES2214305T3 (es) | Utilizacion de la ciamemazina en el tratamiento de la eliminacion brusca de las benzodiazepinas. | |
EP0567498A1 (en) | Pharmaceutical composition containing granisetron and dexamethasone | |
MXPA99008791A (en) | New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders | |
RU98109932A (ru) | Применение 1-(2-нафт-2-илэтил)-4-(3-трифторметилфенил)-1,2,3,6-тетрагидропиридина для получения лекарственных средств, предназначенных для лечения бокового амиотрафического склероза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050307 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050307 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081014 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090113 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090324 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090717 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090820 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090901 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090911 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120918 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130918 Year of fee payment: 4 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |